- Approval complements growing portfolio of cost-saving antiretroviral medications available to patients in the U.S., including recently announced Symfi Lo™ and Cimduo™
- All ARV regimens are being offered at a significant discount to the price of competing products to bring cost savings to the $20 billion U.S. ARV market
PR Newswire
HERTFORDSHIRE, England and PITTSBURGH, March 28, 2018